1
EXHIBIT 10.2
[SCHERING-PLOUGH PHARMACEUTICALS LETTERHEAD]
August 31, 2000
Xx. Xxxxxx X. Xxxxxxx, CEO
COR Therapeutics, Inc.
000 Xxxx Xxxxx Xxxxxx
Xxxxx Xxx Xxxxxxxxx, Xxxxxxxxxx 00000
Dear Xxxxxx:
This is with regard to the Collaboration Agreement, dated April 10, 1995, by
and among COR Therapeutics, Inc. ("COR"), and Schering Corporation and Schering-
Xxxxx Ltd. (collectively "Schering"), as amended, (the "Agreement").
In the Second Amendment to the Agreement, dated November 5, 1999, COR and
Xxxxxxxx agreed to make certain elements of the Second Amendment conditional on
the conduct of a Phase III clinical trial for acute myocardial infarction
("AMI") and have made provision in the Second Amendment for modification of the
Second Amendment based upon the status of such trial as of pre-established
dates, and the parties desire to modify those dates.
The parties are currently negotiating a Third Amendment to the Agreement to
address this and other issues relating to the Agreement. However, Section X.A
of the Second Amendment provides for the termination of certain provisions of
the Second Amendment in the event that "as of June 30, 2000, the JSC has not
voted to conduct the Phase III Study". Therefore, it is hereby agreed that the
deadline for the decision of the JSC with respect to the conduct of the Phase
III Study is extended until September 8, 2000.
Please indicate XXX's acceptance and agreement to the provisions set forth in
this letter by signing below on behalf of COR and returning one signed original
to Schering.
Very truly yours,
Schering Corporation Schering-Plough Ltd.
/s/ XXXXXX X. XXXXX /s/ XXXXX XXXXXXX
------------------------------- ---------------------------------
Xxxxxx X. Xxxxx Xxxxx Xxxxxxx
Executive Vice President Xxxxxxxxx
Xxxxxxxx-Plough Pharmaceuticals
Acknowledged and Agreed to:
COR Therapeutics, Inc.
By: /s/ XXXXXX X. XXXXXXX
---------------------------
Xxxxxx X. Xxxxxxx
Chief Executive Officer
Date: 09/05/00
-------------------------
